Thomas Gysin, MLaw

Switzerland

Thomas Gysin, MLaw

Thomas Gysin advises companies and private individuals on a broad range of national and international contract law matters and in negotiation situations. His practice also covers corporate, commercial and employment law, with a particular focus on M&A, private equity and venture capital. Before entering private practice, he gained more than a decade of experience in legal and commercial roles at leading international companies. In 2024, he won The Negotiation Challenge world championship as a member of the act legal Switzerland team.

Details

  • Zurich Bar Association
  • Member of the Board of Directors at AQA, Thalwil
  • Building the Foundation for Successful Negotiations; Authors: Oliver Gnehm, Fabiola Weilenmann, Thomas Gysin, in: BGPartner Video Publication, 28 September 2022, 10:39 Minutes
  • Negotiation World Champion 2024, The Negotiation Challenge (act legal Switzerland team with Tessa Douma)
  • Attorney at law (Swiss bar admission, 2019)
  • Partner at act legal Switzerland (since 2020, formerly BGPartner Ltd)
  • Leading Swiss law firm
  • Helsana Insurance Company, Zurich
  • UBS, Zurich
  • Swiss Re, Zurich
  • University of Lucerne, MLaw
  • German
  • English

news

track-records

Advising ICAS World Limited on the acquisition of 100% of ICAS Schweiz AG and its subsidiaries in Germany, France, Italy, Austria and Luxembourg.

Advising ICAS World Limited on the acquisition of 100% of ICAS Schweiz AG and its subsidiaries in Germany, France, Italy, Austria and Luxembourg.

Advising Germany's GOLDBECK Holding GmbH on the acquisition of 100 per cent of A. Boss & Co AG, the largest acquisition in the DACH greeting card segment to date.

Advising Germany's GOLDBECK Holding GmbH on the acquisition of 100 per cent of A. Boss & Co AG, the largest acquisition in the DACH greeting card segment to date.

Advising Araris Biotech AG on the sale of all of its shares to Taiho Pharmaceutical Co., Ltd. in a transaction worth up to USD 1.1 billion.

Advising Araris Biotech AG on the sale of all of its shares to Taiho Pharmaceutical Co., Ltd. in a transaction worth up to USD 1.1 billion.

Advising Swixx Biopharma AG on a EUR 200 million syndicated credit facility with UBS, Credit Suisse, Citibank Europe and BNP Paribas (Suisse) SA, including leading the negotiations.

Advising Swixx Biopharma AG on a EUR 200 million syndicated credit facility with UBS, Credit Suisse, Citibank Europe and BNP Paribas (Suisse) SA, including leading the negotiations.

Advising Araris Biotech Ltd on a strategic investment by Samsung Ventures, including leading the negotiations.

Advising Araris Biotech Ltd on a strategic investment by Samsung Ventures, including leading the negotiations.

Thomas Gysin, MLaw

Share via email

act legal BGPartner Ltd
General-Guisan-Quai 38
CH-8027 Zurich
Switzerland

Go to
Offices

Go to Offices